Summary: Aetna, a CVS Health company, modified CPB 0419 governing Graves' ophthalmopathy treatments, effective April 24, 2026. Here's what billing teams need to know before claims hit the payer.
Graves' ophthalmopathy — also called thyroid eye disease (TED) — has seen significant treatment advances over the past few years, and Aetna's Graves' ophthalmopathy coverage policy has moved with them. CPB 0419 in the Aetna system covers the medical necessity criteria, covered indications, and exclusions for treatments ranging from orbital decompression surgery to newer biologic therapies. This policy update landed April 24, 2026, and if your practice treats TED patients with Aetna coverage, your billing team needs to review it now.
The policy document does not list specific CPT, HCPCS, or ICD-10 codes in the data available for this update. That matters — we'll address it directly in the action items below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Graves' Ophthalmopathy Treatments — CPB 0419 |
| Policy Code | CPB 0419 |
| Change Type | Modified |
| Effective Date | April 24, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Ophthalmology, Oculoplastic Surgery, Endocrinology, Rheumatology, Radiation Oncology |
| Key Action | Pull the full CPB 0419 policy document and audit your Graves' ophthalmopathy billing against the updated medical necessity criteria before submitting new claims |
Aetna Graves' Ophthalmopathy Coverage Criteria and Medical Necessity Requirements 2026
Graves' ophthalmopathy is the extrathyroidal manifestation of Graves' disease that affects the orbit. It ranges from mild lid retraction to severe proptosis and compressive optic neuropathy. Aetna's coverage policy for this condition has historically drawn sharp lines between interventions it considers medically necessary and those it considers experimental.
The Aetna Graves' ophthalmopathy coverage policy under CPB 0419 addresses a range of treatment modalities. These include systemic corticosteroids, orbital decompression surgery, orbital radiation therapy, and — more recently — biologic agents such as teprotumumab (Tepezza), which the FDA approved in 2020 for active, moderate-to-severe TED.
Teprotumumab is the treatment category most likely to drive prior authorization friction under this policy. Aetna has previously required documentation of active disease using clinical activity score (CAS) thresholds, plus failure or contraindication to systemic corticosteroids, before approving biologic therapy. If this modification tightens or loosens those thresholds, your prior authorization workflows need to reflect the current criteria — not last year's.
Medical necessity for surgical interventions like orbital decompression has historically required evidence of compressive optic neuropathy, severe proptosis with corneal exposure, or failed medical management. The same logic applies to orbital radiation — Aetna does not cover it as a first-line intervention. If the modification changes the sequencing requirements or adds new step-therapy criteria, that directly affects how your clinical documentation team builds the record for each case.
Because the specific line-by-line changes in this modification are not available in the source data for this post, pull the full CPB 0419 document directly from Aetna before the April 24, 2026 effective date and compare it against the prior version. If you're managing a high volume of TED cases, loop in your compliance officer to do that version comparison formally.
Aetna Graves' Ophthalmopathy Exclusions and Non-Covered Indications
Aetna's prior versions of CPB 0419 have designated certain interventions as experimental, investigational, or unproven for Graves' ophthalmopathy. These exclusions matter because submitting claims for non-covered services without an Advance Beneficiary Notice or equivalent waiver is a denial waiting to happen.
Treatments that have historically landed in Aetna's "not medically necessary" or "experimental" column for this condition include selenium supplementation (despite some evidence in mild TED), rituximab, and certain other biologic agents outside of teprotumumab in specific contexts. Orbital radiation for inactive disease has also been excluded in prior policy language.
If your practice uses any biologic outside the approved pathway — or if you're billing for a newer agent under investigation — check the current CPB 0419 text directly. A claim denial on a high-cost biologic infusion is a significant revenue hit. Don't assume last year's coverage status held through this modification.
Coverage Indications at a Glance
The source data for this policy update does not include a structured list of covered and non-covered indications with code-level detail. The table below reflects the general coverage framework known for CPB 0419, based on Aetna's published policy history. Treat this as a starting framework — verify every row against the current policy document before billing.
| Indication | Status | Notes |
|---|---|---|
| Systemic corticosteroids for active, moderate-to-severe TED | Generally Covered | Medical necessity documentation required; CAS criteria typically apply |
| Teprotumumab (Tepezza) for active, moderate-to-severe TED | Covered with Criteria | Prior authorization required; step therapy through corticosteroids typically required first |
| Orbital decompression surgery | Covered with Criteria | Requires evidence of compressive optic neuropathy, severe proptosis, or failed medical management |
| Orbital radiation therapy | Covered with Criteria | Generally not covered as first-line; typically requires failed medical management |
| Strabismus surgery post-TED stabilization | Covered with Criteria | Typically requires documented stable disease before surgical correction |
| Eyelid surgery for TED-related retraction | Covered with Criteria | Often requires prior surgical steps (decompression, then strabismus) to be completed first |
| Selenium supplementation | Likely Not Covered / Experimental | Aetna has historically excluded this; verify in current document |
| Rituximab for TED | Likely Experimental | Verify current designation in CPB 0419 |
| Orbital radiation for inactive TED | Not Covered | Inactive disease has not met criteria in prior versions |
Aetna Graves' Ophthalmopathy Billing Guidelines and Action Items 2026
Here's what your billing team should do right now, given this modification landed April 24, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the current CPB 0419 document today. Go to Aetna's clinical policy bulletin library and download the April 24, 2026 version. Compare it side-by-side with the prior version. Look specifically at the medical necessity criteria for teprotumumab, orbital decompression, and orbital radiation. Line-by-line comparison is the only way to know what actually changed. |
| 2 | Audit your prior authorization workflows for teprotumumab before submitting new claims. Teprotumumab prior authorization requirements are the highest-stakes piece of this policy. A single denied claim on a full course of Tepezza represents significant lost reimbursement. Confirm that your PA request template matches the updated criteria in CPB 0419 — specifically any CAS thresholds, corticosteroid step-therapy requirements, or disease activity documentation. |
| 3 | Update your medical necessity documentation templates for surgical cases. Orbital decompression billing requires airtight documentation. If the modification changed sequencing requirements or added new clinical criteria, your operative notes and supporting documentation need to reflect that. Brief your oculoplastic surgeons on any changes before they complete documentation for pending cases. |
| 4 | Review your charge capture for any biologics or treatments that may have shifted coverage status. If the modification added or removed a treatment from the experimental designation, claims submitted after April 24, 2026 under the old framework are at risk. Pull a list of open authorizations and pending claims for TED patients and check each one against the current policy. |
| 5 | Flag ICD-10 diagnosis code usage for Graves' ophthalmopathy. The policy does not list specific codes in the available data, but your Graves' ophthalmopathy billing hinges on accurate ICD-10 coding to establish the covered indication. The primary diagnosis code for thyroid ophthalmopathy is H05.00x and related codes in the H05 range, plus E05.00 and related Graves' disease codes. Make sure your coding team is linking the correct diagnosis codes to each procedure to establish medical necessity — an ICD-10 mismatch is one of the fastest paths to a claim denial. |
| 6 | Talk to your compliance officer if you're uncertain about the scope of changes. CPB 0419 covers a broad treatment spectrum. If your practice has significant TED volume across multiple treatment modalities, the compliance risk from misreading this modification is real. Have your compliance officer or billing consultant document the version comparison formally. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Graves' Ophthalmopathy Treatments Under CPB 0419
The Aetna policy data available for this update does not include a specific list of CPT, HCPCS, or ICD-10 codes. This is not unusual for CPB modifications — Aetna often updates clinical criteria without republishing a full code list.
What this means for your billing team: You cannot rely on a code table from this source to build or validate your charge capture. Pull the full CPB 0419 document directly from Aetna and extract the applicable codes from there.
Common procedure categories associated with Graves' ophthalmopathy treatment — and the code families your team should verify against the current policy — include:
- Orbital decompression surgery: Codes in the CPT 67400–67450 range for orbital surgery
- Strabismus surgery: CPT codes in the 67311–67340 range
- Eyelid procedures for TED-related retraction: CPT codes in the 67900 range for eyelid repairs
- Orbital radiation therapy: Covered under radiation oncology CPT families; verify with your radiation oncology billing team
- Teprotumumab infusion: HCPCS J-code for teprotumumab (J3999 or a drug-specific J-code depending on payer assignment); confirm the active HCPCS code with Aetna's drug policy
Do not bill codes based on this general framework alone. Use it to know where to look — not as a substitute for the actual policy document.
Get the Full Picture for CPT 67400
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.